The contribution of changes in cis-regulatory elements or trans-acting factors to interspecies differences in gene expression is not well understood. The mammalian β-globin loci have served as a model for gene regulation during development. Transgenic mice containing the human β-globin locus, consisting of the linked embryonic (ε), fetal (γ) and adult (β) genes, have been used as a system to investigate the temporal switch from fetal to adult haemoglobin, as occurs in humans. Here we show that the human γ-globin (HBG) genes in these mice behave as murine embryonic globin genes, revealing a limitation of the model and demonstrating that critical differences in the trans-acting milieu have arisen during mammalian evolution. We show that the expression of BCL11A, a repressor of human γ-globin expression identified by genome-wide association studies, differs between mouse and human. Developmental silencing of the mouse embryonic globin and human γ-globin genes fails to occur in mice in the absence of BCL11A. Thus, BCL11A is a critical mediator of species-divergent globin switching. By comparing the ontogeny of β-globin gene regulation in mice and humans, we have shown that alterations in the expression of a trans-acting factor constitute a critical driver of gene expression changes during evolution.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
We are grateful to K. Peterson and H. Fedosyuk for providing β-locus mice, K. Gaensler for the A20 and A85 strains of β-locus mice, and T. Jacks for providing the K-RasG12D mice. We thank J. Palis and P. Kingsley for providing mouse embryonic globin antibodies, H. Mikkola and B. Van Handel for providing sorted human samples, and R. Byron and A. Telling for technical support. We thank L. Zon, K. McGrath, P. Kingsley, J. Palis, M. Kowalczyk and T. Menne for advice and discussions. This work was supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) (S.H.O. and M.G.) and the National Cancer Institute (P.W.T.). S.H.O. is an Investigator of the Howard Hughes Medical Institute (HHMI). C.R.W. is a special fellow of the Leukemia & Lymphoma Society. T.R. is supported by a fellowship from the American Society of Hematology. J.X. is an HHMI fellow of the Helen Hay Whitney Foundation. V.G.S. is supported by a Medical Scientist Training Program Award from the NIH and G.C.I. is supported by a NCI postdoctoral fellowship.
Author Contributions V.G.S., J.X. and S.H.O. conceived the study design. V.G.S., J.X., T.R., C.R.W., Y.F., M.I. and M.A.B. performed the experiments. V.G.S., J.X., T.R., C.R.W., M.G., M.A.B. and S.H.O. analysed data. G.C.I., S.D.M. and P.W.T. developed and contributed a new mouse line. V.G.S., J.X. and S.H.O. wrote the paper. All authors read, helped revise, and approved the manuscript.
This file contains Supplementary Notes, Supplementary References and Supplementary Figures 1-10 with Legends.
About this article
Indian Journal of Hematology and Blood Transfusion (2019)